In ASX News, Exopharm

Osteoarthritus Animal Study
This trial involved multiple 4 x weekly dosing of rats with two naïve EV products Cevaris and Plexaris. The study demonstrated that the products were well-tolerated by the animals with no toxicity, no adverse events or knee swelling though to termination. The rats were given a chemical to induce OA, however, the damage caused was too severe to measure tissue regeneration because there were no cartilage cells available to respond to the exosome treatments. According to Cellvax, the contract research organisation which conducted the trial, in order to test the efficacy of the naïve EV treatments Cevaris and Plexaris, the dose of chemical would need to be optimised to induce less severe damage in the rats knee joints so there are cartilage cells for the exosomes to have a regenerative effect on.

Recommended Posts